First patient recruited into Alzinova’s phase 1b clinical study with the oligomer-specific ALZ-101 vaccine against Alzheimer’s disease

Date: 2021-10-29

Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments of Alzheimer’s disease by specifically targeting neurotoxic amyloid-beta oligomers, today announces that the first patient has been recruited into its phase 1b clinical study with ALZ-101 in Finland.